Sunday, August 1, 2021

Pfizer, BioNTech amp up COVID-19 vaccine dose target again—this time to 2.5B doses


Pfizer and BioNTech have hustled to produce as many COVID-19 vaccine doses as possible this year, and that effort keeps paying off. After jacking up their dose-delivery goal to 2 billion earlier this year, the companies are adding hundreds of millions of doses to their target.

The companies now aim to produce 2.5 billion doses of their Comirnaty vaccine in 2021, BioNTech said Tuesday. Manufacturing “optimization,” plus a recent factory approval in Marburg, Germany—and regulatory approvals for the six-dose vial—are driving the increase, the company said.

And this may not be the last boost to that goal. Pfizer and BioNTech are expanding their production and supplier network, and additional talks are underway.

Meanwhile, under vaccine purchase orders the partners have inked for 2021, BioNTech stands to collect around €9.8 billion, the company said Tuesday.

During a Reuters interview earlier this month, Pfizer CEO Albert Bourla, Ph.D., said the company would “clearly” exceed its supply goal of 2 billion doses. At the time, he projected the partners could make 2.3 billion to 2.4 billion doses. Previously, the companies had said they’d manufacture 1.3 billion doses by year-end.

Like other COVID-19 vaccine players, BioNTech and Pfizer are working 24/7 to produce as many doses of their authorized vaccine as possible. The other mRNA vaccine company with an authorized shot, Moderna, has said it’s working to produce up to 1 billion doses this year.

Beyond mRNA, Johnson & Johnson has said it’s targeting 1 billion doses of its adenovirus-based shot for 2021, while Novavax and AstraZeneca are eying multibillion-dose outputs this year.

RELATED: BioNTech nabs EU approval for former Novartis plant tapped in COVID-19 vaccine production push

As of last week, Pfizer and BioNTech had supplied more than 200 million doses of the vaccine globally. The partners have taken 2021 purchase orders of 1.4 billion doses, and talks are underway for more potential purchases.

BioNTech, which was a clinical-stage biotech before its shot scored emergency authorizations, also posted its first sales last year. The company pulled in €270.5 million after the shot’s December FDA authorization.



Source link

Stay Connected

1,605FansLike
11,000FollowersFollow
342FollowersFollow
775FollowersFollow

Latest Articles

Need to create vigilance and awareness on zoonotic diseases: India’s Health Minister

The COVID-19 pandemic has highlighted the need of creating vigilance and awareness on zoonotic diseases, informed Union Health Minister Mansukh Mandaviya while virtually inaugurating...

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...